Table 4.
Characteristic of AML patients in validation cohort
| Variable | UBE2E1 high n = 25 | UBE2E1 low n = 25 | p value |
|---|---|---|---|
| Median age | 43.08 | 43.25 | 0.567 |
| Female, no. (%) | 10(40) | 13(52) | 0.395 |
| Secondary or treatment-related AML, no. (%) | 2(8) | 2(8) | >0.99 |
| FAB subtype , no. | 0.838 | ||
| M1 | 3 | 3 | |
| M2 | 10 | 12 | |
| M4 | 7 | 5 | |
| M5 | 1 | 3 | |
| M6 | 2 | 0 | |
| NA | 2 | 2 | |
| Median WBC, 109/L (range) | 6.83(0.3–244.38) | 23.88(0.68–366) | 0.289 |
| Median BM plasts, %, (range) | 49.5(11–94) | 65.5(22–90.5) | 0.175 |
| Median platelet count, 109/L (range) | 39(4–151) | 35.5(4–180) | 0.918 |
| CEBPA mutated, no. (%) | 2(8) | 5(20) | 0.179 |
| Missing date | 1 | 3 | |
| NPM1 mutated, no. (%) | 2(8) | 4(16) | 0.327 |
| Missing date | 1 | 3 | |
| IDH1 mutated, no. (%) | 0 | 0 | >0.99 |
| Missing date | 1 | 3 | |
| FLT3-TKD mutated, no. (%) | 0 | 1(4) | 0.296 |
| Missing date | 1 | 3 | |
| FLT3-ITD mutated, no. (%) | 0 | 2(4) | 0.149 |
| Missing date | 1 | 3 | |
| AML1/ETO mutated, no. (%) | 4(16) | 6(24) | 0.389 |
| Missing date | 1 | 3 | |
| C-KIT D816V mutated, no. (%) | 1(4) | 2(8) | 0.504 |
| Missing date | 1 | 3 | |
| CBEB-MYH11 mutated, no. (%) | 2(8) | 3(12) | 0.568 |
| Missing date | 1 | 3 |